Quality of Evidence: Very Low
Coadministration has not been studied. As kanamycin is eliminated unchanged predominantly via glomerular filtration, there is little potential for interaction with tenofovir-DF via competition for active renal transport mechanisms. However, both kanamycin and tenofovir are potentially nephrotoxic and tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. If concomitant use of tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be monitored closely.